IMMUNOCORE HLDGS ADS/1 Capital Reinvestment Ratio
IMMUNOCORE HLDGS ADS/1 capital reinvestment ratio. IMMUNOCORE HLDGS ADS/1 (6YG) has a Capital Reinvestment Ratio of 0.05x as of June 2026, meaning it reinvests 0% of its operating cash flow (€15.93 Million) in capital expenditures (€786.00K). Check IMMUNOCORE HLDGS ADS/1 (6YG) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of IMMUNOCORE HLDGS ADS/1 (2023–2024)
Capital reinvestment ratio of IMMUNOCORE HLDGS ADS/1 from 2023 to 2024. This chart tracks IMMUNOCORE HLDGS ADS/1's Capital Reinvestment Ratio across 2 annual periods. Also explore IMMUNOCORE HLDGS ADS/1 (6YG) equity growth momentum to track the company's year-over-year net asset growth rate.
IMMUNOCORE HLDGS ADS/1 Capital Reinvestment Ratio by Year (2023–2024)
IMMUNOCORE HLDGS ADS/1 capital reinvestment ratio by year from 2023 to 2024. For the full cash flow conversion analysis, see how efficiently does IMMUNOCORE HLDGS ADS/1 generate cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.20x | €26.06 Million | €5.17 Million | ▼ -89.2% |
| 2023 | 1.85x | €2.94 Million | €5.42 Million | — |